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Photodynamic therapy (PDT) is a popular technique for skin cancer treatment. Protoporphyrin IX, which
is a photosensitizing agent, converted enzymatically from the prodrug 5-aminolevulinic acid (ALA), is
used as a photosensitizer in PDT for cancer. However, ALA penetrates with difﬁculty through intact skin;
therefore, improving delivery systems for ALA in the skin will play an important role in ALA-PDT.
Enhancement of ALA skin penetration can be achieved by physical methods, such as iontophoresis, laser,
microneedles, ultrasound, and by adding chemical penetration enhancers, such as, dimethyl sulfoxide,
oleic acid, and others, whereas some researches used lipophilic ALA derivatives and different vehicles to
improve the transdermal delivery of ALA. This review introduces several enhancement techniques for
increasing ALA permeation through the skin.
Copyright  2011, Taiwanese Dermatological Association. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Skin cancer is the most common of all pathologies related to
cancerous diseases.1 Nearly two million new cases are diagnosed
yearly, and that continues to increase worldwide. Photodynamic
therapy (PDT) is a new modality for skin cancer treatment. In PDT,
three components are combined to induce tumor destruction:
a photosensitizer, light, and oxygen.2 It is based on the accumulation
of a porphyrin-related photosensitizer in tumor cells and its
subsequent destruction when exposed to visible light. Singlet
oxygen species are produced, which damage membranes and
organelles, causing cell death and tumor ablation.3
The photosensitizer precursor: 5-aminolevulinic acid
The original photosensitizing mixture was termed the hemato-
porphyrin derivative (HPD). In 1975, Dougherty et al4 reported that
HPD in combination with red light could completely eradicate
mouse mammary tumor growth. Clinical trials were subsequentlyGraduate Institute of Natural
oad, Kweishan, Taoyuan 333,
iwanese Dermatological Associatioinitiated with HPD to treat patients with bladder cancer and skin
tumors.5 There are now increasing numbers of photosensitizing
prodrugs being used clinically, such as 5-aminolevulinic acid (ALA).
ALA was approved by the U.S. Food and Drug Administration and is
currently used in PDT. ALA, which is not a photosensitizer, is the
precursor of protoporphyrin IX (PpIX), the derivatives of which are
used as photosensitizers in PDT for cancer.6
ALA is synthesized in mitochondria under a negative feedback
control mechanism by heme. In principle, the reaction initiated
from the condensation of glycine and succinyl CoA, which is cata-
lyzed by ALA-syntase, produces the ﬁrst intermediate, which is
further synthesized through a series of biochemical reactions. After
those reactions, PpIX is converted into heme by ferrochelatase in
the presence of iron (Figure 1).1
Transdermal drug delivery system
The skin is the largest organ of the human body. It is composed of
three main histological layers: the epidermis, dermis, and subcu-
taneous tissues. The epidermis is further divided into two parts: the
stratum corneum (SC) and viable epidermis, which includes other
layers of the epidermis, such as the stratum granulosum, stratum
spinosum, and stratum basale (Figure 2).7 The SC is the ﬁnal
product of epidermal cell differentiation, consists of 10e15 layers of
corneocytes, and varies in thickness from approximately 10e15 mmn. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 Heme synthesis pathway. ALA¼ 5-aminolevulinic acid.
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ered “brick and mortar” structure,8 consisting of various lipids
(5e15%), including phospholipids, glycosphingolipids, cholesterol
sulfate, and neutral lipids. The main protein (75e85%) in the SC is
keratin.9 Intercellular lipids in the SC have a special role in regu-
lating the SC barrier function.10e12
Transdermal drug delivery systems (TDDSs) have been in clin-
ical use for more than 30 years.13 TDDSs offer several advantages
compared with the oral route and injections, such as the
following14,15:
 Reduction of ﬁrst-pass metabolism in the liver;
 Improved patient compliance;
 Delivery topically and directly to the morbid area; and
 Reduced side effects of drugs.Figure 2 The epidermis consists of the stratum corneum, straHowever, TDDSs also have limitations, such as the skin state;
properties of the drugs (e.g. molecular mass, dissociation coefﬁ-
cient [pKa], and partition coefﬁcient); types of vehicles; and the
concentration of the drug.15 Because the SC has a barrier function,
not all drugs are suitable for TDDSs; thus, several studies used
permeability-enhancing techniques to increase the penetration of
drugs.16e18
Use of ALA for topical PDT
Application of ALA for PDT was ﬁrst introduced by Kennedy et al.19
It was reported that ALA-PDT is useful for treating superﬁcial skin
cancers, actinic keratoses,20 psoriasis,21 cutaneous T-cells,22 basal
cell carcinoma,23 and squamous cell carcinoma.24 An ideal photo-
sensitizer shows a high tumor-to-normal-tissue ratio, exhibitstum granulosum, stratum spinosum, and stratum basale.
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from the body. In addition, ALA-PDT can be used as a long-term
treatment without causing the accumulation of PpIX in normal
skin.25 ALA is a hydrophilic molecule with a molecular weight of
167.6.26 According to the skin permeability theory, ALA has difﬁ-
culty penetrating intact skin. The SC is the main barrier for percu-
taneous penetration of this exogenous substance. The permeability
of hydrophilic ALA through intact skin is always low, making it
difﬁcult to achieve the desired therapeutic beneﬁts. Numerous
strategies were proposed to improve these penetration problems,
such as modifying ALA’s structural properties, and changing the
skin’s state by chemical and physical enhancement methods.27,28
Chemical modiﬁcation of the lead compound (ALA
derivatives)
Despite the SC barrier, ALA might be able to penetrate through the
skin and into tumors after topical application because of its small
molecular weight.29 However, ALA is hydrophilic and zwitterionic,
characteristics that make it difﬁcult for ALA to penetrate the SC
barrier. Therefore, lipophilic ALA ester derivatives have better
potential for clinical use comparedwith ALA.30 Themost frequently
investigated ALA derivative is methyl (M)ALA.
According to the determination of the partition coefﬁcients of
different alkyl esters, these compounds showed an increased
afﬁnity for the SC; hexyl-ester ALA and octyl-ester ALA showed the
highest partition coefﬁcients (Table 1) and increased afﬁnities for
the SC. The in vitro skin permeation test revealed that hexyl-ester
ALA had a higher permeated amount than ALA (by about threefold)
and other ester derivatives. Moreover, hexyl-ester ALA and octyl-
ester ALA, but not ALA, were retained in the viable epidermis and
dermis.31 However, Juzeniene et al32 applied creams containing
0.2%, 2%, and 20% of ALA, MALA, and hexyl-ester ALA, respectively,
to normal human skin of six volunteers to evaluate the topical
application of these prodrugs. The amount and distribution of
porphyrins formed in the skin were investigated noninvasively by
means of ﬂuorescence spectroscopy. The results showed that MALA
induced comparably less PpIX in normal human skin than ALA and
hexyl-ester ALA at low dosages (0.2% and 2%), whereas higher PpIX
ﬂuorescence was found in the ALA treatment group than that in the
MALA and hexyl-ester ALA groups at a high dosage (20%).32
Pretreatment with physical penetration enhancers
Recently, several innovative strategies were used to improve ALA
penetration into skin, including iontophoresis,33,34 lasers,24,35
microneedles (MNs),36,37 and ultrasound38 (Table 2).
Iontophoresis is a strategy that induces ionizable drugs through
intact skin by the administration of a continuous, direct electrical
current. It enhances drug transport across the SCwithout signiﬁcant
perturbation of the skin barrier.39 ALA is a zwitterion at physio-
logical pH,2 indicating that the iontophoretic mechanism of elec-
trotransport is primarily electro-osmosis, with little or noTable 1 ALA and alkyl esters: general structure¼HCl‧NH-CH2-CO-CH2-CH2CO-OR,
molecular weight, and partition coefﬁcients.
Compounds R Molecular mass (g/mol) Log KSC/W*
ALA H 167.6 1.3726
Methyl-ester ALA CH3 181.6 0.2066
Butyl-ester ALA (CH2)3CH3 223.8 0.2969
Hexyl-ester ALA (CH2)5CH3 251.8 0.9122
Octyl-ester ALA (CH2)7CH3 279.6 1.0221
* Log KSC/W: decadic logarithm of partition coefﬁcients of ALA and its n-alkyl
esters between the stratum corneum and water (KSC/W).31
ALA¼ 5-aminolevulinic acid.contribution from electromigration. In addition, one study found
that ALA transport is more efﬁcient from the anode than the
cathode.34 Lopez et al40 reported the effect of pH on iontophoretic
delivery of ALA; they used anodal iontophoresis to evaluate the ALA
transport efﬁciency at different pH values. The results showed that
there was a signiﬁcant increase, about 100 mM, at pH 7.4.40 Some
researches also estimated the optimized conditions for ALA elec-
trotransport into and through the skin by adjusting the formulation
composition and ionic strength. One group compared the anodal
iontophoreticﬂuxof ALA froma10% solutionwith the drug’s passive
ﬂux from the same formulation to which 5% dimethyl sulfoxide
(DMSO) had been added, and transport of ALA across the skin and
the amount of prodrug delivered into the skin (SC and [epi-
dermisþ dermis]) were fourfold greater with iontophoresis
compared with passive application of the DMSO formulation.33
Iontophoresis can also be used to control the delivery of ALA
esters into the skin. Lopez et al34 studied enhanced delivery of ALA
esters by iontophoresis in vitro.34 They used anodal iontophoretic
transport of ALA esters through porcine skin in an in vitro perme-
ation test under a current of 0.5 mA/cm2 for 2 hours. The results
indicated that positively charged ALA esters with moderate lip-
ophilicity showed an increasing iontophoreticﬂux through the skin.
Greater than 50-fold enhancement compared with the zwitterionic
parent ALA was observed for MALA. Iontophoresis of MALA and
hexyl-ester ALA also increased the amount of prodrug delivered into
the skin. The efﬁciency of ALA ester permeation by iontophoresis,
compared with ALA itself, and the amount of prodrug that was
transported into and across the skin were greatly enhanced.
Lasers are a very popular technology that is used for medical
diagnoses and therapeutic purposes. They can effectively enhance
drug delivery through the skin by ablating the SC with minimal
residual thermal damage. Shen et al35 evaluated the in vitro
percutaneous absorption and in vivo PpIX accumulation in skin and
tumors after topical ALA application combined with erbium
yttriumealuminumegarnet (Er:YAG) laser enhancement. ALA
penetration after surface treatment with an Er:YAG laser also
produced higher accumulations of PpIX within subcutaneous
tumors of the superﬁcial skin comparedwith those of the untreated
group. The enhancement ratios of laser-treated skin ranged from
1.7-fold to 4.9-fold compared with those of the control group
depending to the ﬂuence used. Although it effectively enhanced
ALA delivery, the skin needed 3e5 days to recover to a normal
status after Er:YAG laser treatment. Lee et al24 used a fractional
Er:YAG laser to enhance skin permeation of ALA. The ﬂux of ALA
through laser-treated nude mouse skin and porcine skin showed
higher levels than that through intact skin by 27e124-fold and
3e260-fold, respectively. The in vivo skin penetration depth also
increased after laser treatment according to confocal scanning laser
microscopic (CSLM) observations.
The ﬁrst study using MNs as an enhancing technique to increase
transdermal drug delivery was published in 1998. The overarching
motivation for MNs is that they provide aminimally invasivemeans
to drive molecules into the skin. Inserting drug molecules into the
skin through MNs causes no pain or bleeding. Furthermore, MNs
allow the delivery of drugs from dry dissolvable MNs rather than
liquids.41e43 Donnelly et al36 used silicon MN arrays to enhance the
skin penetration of ALA in vitro and in vivo. Puncturing excised
murine skin with 6 7 arrays of MNs 270 mm in height, with
a diameter of 240 mm at the base and an interspacing of 750 mm, led
to a signiﬁcant increase in the transdermal delivery of ALA released
from a bioadhesive patch containing 19 mg/cm2 ALA. MN puncture
enhanced ALA delivery to the upper regions of excised porcine skin,
but at a mean depth of 1.875 mm. In vivo experiments on nude
mice showed that siliconMNpuncture could reduce the application
time and ALA dose required to induce high levels of the
Table 2 Different types of enhancement methods, the model used, and efﬁcacy in previous studies.
Enhancement methods Authors Animal or skin model Efﬁcacy
Chemical penetration enhancers
DMSOþ EDTA Malik et al46 7- to 9-wk-old female BALB/c mice
subcutaneously
bearing transplanted C26 colon carcinomas
In skin: ALAeDMSOeEDTA>ALAeDMSO>ALA
De Rosa et al23 Healthy hairless mouse skin In vitro increased the ALA permeation amount
In vivo signiﬁcantly increased by about 2.5-fold
the amount of PpIX
Oleic acid Pierre et al47 In vitro: full-thickness porcine
ear dorsal skin
In vivo: 6- to 8-wk-old male
hairless mice skin
Both in vitro and in vivo results showed oleic
acid’s potential as an optimizer of ALA skin delivery
Different vehicles
Lotion and cream Casas et al51 Male BALB/c mice 12 wk old Maximal accumulation was found in the tumor
3 hr after ALA application with both cream and
lotion preparations
Cubic gel, HEC gel, and patch Valenta et al53 Porcine abdominal skin ALA permeation through porcine skin after 48 hr
was the highest from the patch (80.3%) followed
by the cubic gel (66.4%)
Liposomes Pierre et al57 Skin of male HRS/J hairless
mice 4 wk old
Skin retention in the skin layers signiﬁcantly
increased by SCLL formulation in the epidermis
without SCþ dermis compared with values for
the aqueous solution
W/O, Bc, and O/W
microemulsions
Araujo et al59 In vitro: pig ear skin
In vivo: skin of HRS/J hairless
mice 6e9 wk old
The developed microemulsion carried ALA to the
deeper skin layers, increasing the PpIX of the skin
Vehicleþ chemical enhancer
Saline lotion alone or
with DMSO, cream,
liposomes, and Vaseline
Casas et al52 Male BALB/c mice 12 wk old Porphyrin accumulations in saline lotion,
without and with 10% DMSO (mean SD),
were 1.75 0.25 mg/g and 2.09 0.39 mg/g,
respectively.





Auner et al58 Porcine abdominal skin In vitro permeation, pre-impregnation of porcine
skin with liposomeþ phloretin or 6-ketocholestanol
increased the ALA diffusion by about 1.7-fold at pH 7.0.
Enhancement of an ALA and CP combination with 6-ketocholestanol
as the donor was 3.5-fold higher
Physical enhancer
Iontophoresis Lopez et al40 Pig ears (w700 mm) In vitro: at pH 7.4, it was achieved by increasing the drug
concentration in the anodal formulation to 100 mM
Iontophoresis Lopez et al33 Pig ears (w700 mm) In vitro: fourfold greater with iontophoresis compared with the
passive application of a DMSO formulation
Er:YAG laser Shen et al35 Female BALB/c nude mice 7e8 wk old Er:YAG laser irradiation of the skin increased the in vitro and
in vivo efﬁcacies of topical ALA delivery
Fractional Er:YAG laser Lee et al24 In vitro: 8-wk-old female nude mice skin
and ear skin of 1-wk-old pigs
In vivo: 8-wk-old female nude mice
ALA permeation was effectively enhanced by ablating the
SC with a low-ﬂuence fractional laser
MNs Donnelly et al36 Female BALB/c athymic nude
mice 7e8 wk old
MN puncture reduced the application time and ALA dose
Ultrasound Ma et al38 Female BALB/c athymic nude
mice 7e8 wk old
bearing WiDr human colon
adenocarcinomas
Ultrasound increased ALA delivery into the tumor and skin
Physical enhancerþALA esters
IontophoresisþALA esters Lopez et al34 Pig ears (w700 mm) Iontophoresis increased ALA ester delivery into the skin
MNsþMALA Mikolajewska et al37 Human skin (14 healthy volunteers) MN efﬁciency of topical PDT improved the cutaneous
delivery of ALA and MALA, without an increase in side effects
DMSO¼ dimethyl sulfoxide ; EDTA¼ ethylenediaminetetraacetic acid; PpIX¼ protoporphyrin IX; ALA¼ 5-aminolevulinic acid; HEC¼ hydroxyethyl cellulose;W/O¼water in
oil; Bc¼ bicontinuous; O/W¼ oil in water; SD¼ standard deviation; CP¼ cetylpyridinium chloride; MNs¼microneedles; MALA¼methyl 5-aminolevulinic acid.
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ALA esters in increasing ALA cell permeation,30 the use of some of
these compounds to treat skin cancer is still a matter of discussion,
because of the fact that they appear to diffuse slowly across the
SC.27 Among all ALA derivatives, MALA is used the most frequently.
One study used the skin of 14 healthy volunteers to determine the
impact on skin pretreated with MNs on ALA- and MALA-induced
PpIX production. It found that MNs increased the PpIX ﬂuorescence
after a 4-hour incubation time with 2% and 8% ALA or MALA. MN
pretreatment caused no pain during light exposure and induced no
erythema.37Ultrasound is cyclic sound pressure with a frequency greater
than the upper limit of human hearing. In 1982, there was research
that showed that ultrasound could increase the blood circulation in
tumors to improve the uptake of drugs.44 Ma et al38 demonstrated
that ultrasound could increase PpIX production both in tumors and
skin of BALB/c nude mice bearing WiDr human colon adenocarci-
nomas. They also demonstrated that pulsed irradiated ultrasound
(1 MHz) with an average intensity of 3 W/cm2 for 10 minutes to the
tumor area after administration of ALA (20% in an oil/water [O/W]
emulsion applied topically to the surface of the tumor for 0.5e3
hours) increased the amount of PpIX in the tumors by
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PpIX in the tumors after ultrasound treatment for 1 hour was
similar to that of ALA applied alone for 3 hours.
Pretreatment with chemical penetration enhancers
Penetration enhancers may act by one or more of three main
mechanisms9: (1) disruption of the highly ordered structure of SC
lipids; (2) interaction with intercellular proteins; and (3) improved
partitioning of the drug, coenhancer, or solvent into the SC.
DMSO was one of the earliest and most widely studied pene-
tration enhancers. DMSO may also extract lipids, making the horny
layer more permeable by forming aqueous channels.9 Some studies
showed it to be effective in promoting both hydrophilic and lipo-
philic permeants.45 Malik et al46 reported topical ALA application
using three different creams (20% ALA alone; ALA with 2% DMSO;
and ALA, DMSO, and 2% edetic acid disodium salt [ethyl-
enediaminetetraacetic acid (EDTA)]) applied to mice bearing
subcutaneously transplanted C26 colon carcinomas. PpIX produc-
tion in the tumor and skin overlying the tumor was studied by
laser-induced ﬂuorescence and chemical extraction. The PpIX
concentration after treatmentwas higher in the skin than that in the
tumor. The efﬁciency of porphyrin production in the skin by the
creams usedwas in the following order: ALAeDMSOeEDTA>ALAe
DMSO>ALA.46 De Rosa et al23 used 20% DMSO in O/Wemulsions to
increase the in vitro permeation of ALA through hairlessmouse skin.
Other in vivo studies demonstrated a signiﬁcant increase of about
2.5-fold in the amount of PpIX extracted from healthy hairless
mouse skin after 3 hours of treatment with an O/W emulsion con-
taining 10% ALA (w/w), 3% EDTA (w/w), and 20% DMSO (w/w). By
CSLM imaging, itwas concluded that the association of 10%ALAwith
20% DMSO in O/W emulsions induced a signiﬁcant increase in PpIX
production and accumulation in hairless mice skin. The effect of
EDTA may be associated with the inhibition of ferrochelatase, an
enzyme that converts PpIX into heme in the presence of iron. In that
report, the presence of EDTA caused only a slight nonsigniﬁcant
increase in the PpIX concentration in the skin. However, a subse-
quent report indicated that the combination of ALA, EDTA, and 20%
DMSOmay enhance the delivery of ALA to the skin in topical PDT.23
Some reports using electron microscopy showed that a discreet
lipid domain is inducedwithin SC lipid bilayers on exposure to oleic
acid, which enhanced the permeation of drugs across the skin.45
Therefore, Pierre et al47 reported oleic acid as an optimizer of the
skin delivery of ALA in PDT. They measured the in vitro skin
penetration and retention of ALA (1%) in the presence and absence
of oleic acid (2.5%, 5.0%, and 10.0%) in propylene glycol using
porcine ear skin as the membrane, and the in vivo accumulation of
PpIX, 4 hours after application, was determined ﬂuorometrically in
healthy mice skin by chemical extraction of skin samples. The
results showed that the ﬂux and in vitro retention of ALA in viable
epidermis increased in the presence of 10.0% oleic acid. The
amounts of PpIX, evaluated both by chemical tissue extraction and
in vivo measurements by an optical ﬁber probe, increased after
applying ALA formulations containing 5.0% and 10.0% oleic acid.
Moreover, in vivo kinetic studies showed an increase in skin PpIX
accumulation when formulations containing 10% oleic acid were
used; PpIX accumulation was also maintained for a longer period
compared with the controls.
Skin penetration of ALA with different vehicles
The half-life of ALA in the body is quite short (about 45 minutes)
because of its insufﬁcient stability under physiological condi-
tions.48,49 Vehicles may serve as a solubilization matrix, as a local
depot for the sustained release of dermally active compounds, asa permeation enhancer, or as a rate-limiting membrane barrier to
modulate systemic absorption of drugs through the skin.50
In 1999, Casas et al51 reported the topical application of ALA
delivered in different vehicles to the skin overlying a tumor and
normal skin of mice. They used a lotion and cream, and the
maximal accumulation was found in the tumor 3 hours after ALA
application with both the cream and lotion preparations. The
results showed that normal skin tissues and those overlying the
tumor had different kinetic patterns, reﬂecting histological changes
after the latter had been invaded by tumor cells. ALA lotion applied
to the skin overlying the tumor induced higher accumulation of
porphyrins in the tumor than the cream, and the lotion applied to
normal skin appeared to be the most efﬁcient for inducing total-
body porphyrins. The following year, they also studied ALA in
a saline lotion alone or with DMSO, cream, liposomes, and Vaseline,
after topical application in a murine subcutaneous adenocarcinoma
model. By measuring the uptake of 14C-labeled ALA, porphobili-
nogen accumulation, and some heme enzyme activities, they
observed the effect of DMSO on porphyrin synthesis and ALA
penetration through the skin. ALA in the saline lotion, without or
with 10% DMSO, proved to be the most efﬁcient vehicle for tumor
porphyrin accumulation (mean standard deviation values are
1.75 0.25 mg/g and 2.09 0.39 mg/g, respectively), whereas cream
and liposomes induced lower levels and similar porphyrin accu-
mulations of about 0.60 mg/g. Using the ALAþDMSO saline lotion,
a higher porphyrin accumulation was found in skin overlying the
tumor tissue and in the ﬁrst 2 mm of the tumor, probably because
of either increased ALA penetration, greater interconversion to
porphyrin, or greater retention of ALA and/or porphyrins.52
A new cubic gel and patch system containing additional carra-
geenan as the matrix was used as a vehicle for ALA. Valenta et al53
reported skin permeation and stability studies of ALA in the new gel
and patch preparations. They used three vehicles: a cubic gel,
a hydroxyethyl cellulose gel, and a patch. The in vitro ALA perme-
ation through porcine skin after 48 hours was highest at 80.3% from
the patch formulation, followed by the cubic gel at 66.4%. However,
only about 40% of the ALA was chemically stable after 14 days of
storage in the patch formulation, whereas no degradation of ALA
was detected in the cubic gel over 90 days of observation.53
Liposomes are one of the best drug delivery systems for low-
molecular-weight drugs, imaging agents, peptides, proteins, and
nucleic acids.54 Liposomes are microscopic vesicles consisting of
one or more membrane-like phospholipid bilayers surrounding an
aqueous medium.55 According to their particle size, liposomes are
nanospheres or microspheres. Small unilamellar vesicles have
dimensions of 20e100 nm, large unilamellar vesicles are larger
than 100 nm, and multilamellar vesicles have dimensions
exceeding 500 nm. Lipophilic agents are incorporated into the
bilayers, whereas hydrophilic agents are found within the water
phase inside the vesicles.56 Pierre et al57 worked on a delivery
system for ALA based on liposomes with a lipid composition
combined to obtain 10 mg of a mixture containing lipids at the
following concentrations: ceramide (50%), cholesterol (28%), pal-
mitic acid (17%), and colesteryl sulfate (5%), in close approximation
of the composition of mammalian stratum corneum lipid lipo-
somes (SCLLs) to optimize its skin delivery in PDT for skin cancers.
SCLL encapsulated around 5.7% ALA, and the respective sizes were
around 500 nm and 400 nm for SCLLs and SCLLs containing ALA.
The in vitro permeation proﬁle was characterized using hairless
mouse skin mounted in a modiﬁed Franz diffusion cell, and the
results showed that SCLL preparations presented signiﬁcantly
higher skin retention in the epidermis without the SCþ dermis,
with decreased skin permeation compared with an aqueous solu-
tion. In contrast, Auner et al58 used different-pH ALA solutions
(cetylpyridinium chloride and benzalkonium chloride at pH 7.0 and
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sodium-1-pentanesulfonic acid monohydrate at pH 4.0) combined
with liposomes containing phloretin and 6-ketocholestanol. Pre-
impregnation of porcine skin with liposomes containing phloretin
and 6-ketocholestanol as enhancers increased ALA diffusion by
about 1.7-fold at pH 7.0. The transport enhancement of ALA and
cetylpyridinium chloride combined with 6-ketocholestanol as the
donor was 3.5-fold higher.
Microemulsions are compositions of oil, water, surfactants, and
cosurfactants. Compared with ordinary emulsions, microemulsions
form on simple mixing of the components, and do not require high-
shear conditions, are easily prepared, and have low viscosity.
Microemulsions are of two basic types: O/Wandwater in oil (W/O).
ALA was incorporated in W/O, bicontinuous (Bc), and O/W micro-
emulsions produced by the titration of ethyl oleate and PEG-8
caprylic/capric glyceride (Labrasol): polyglyceryl-6 dioleate (3:1)
mixtures with water. The in vitro and in vivo skin permeation of
ALA was investigated using diffusion cells and CSLM, respectively.
The O/W microemulsion decreased the ALA diffusion coefﬁcient
and retarded the drug release, but compared with other ALA
carriers, it also signiﬁcantly increased the in vitro drug skin
permeation. In another study,59 the in vivo permeation of an ALA
microemulsion was observed by CSLM, and the red ﬂuorescence of
the skin homogeneously increased in the deeper skin layers,
probably because of the formation of the photoactive PpIX.Conclusions
PDT is a widely used technique to treat skin diseases, whereas ALA
andMALA are the twomost-often used drugs in PDT. Because there
are some difﬁculties in ALA penetration through intact skin, many
researches have used animal and human skins as in vitro models to
evaluate whether the use of enhancers is beneﬁcial for ALA-PDT
efﬁciency. Combinations of these methods, including the design of
carriers, prodrugmodiﬁcation, and the use of physical and chemical
enhancers, are trends for PDT in the future.References
1. Lopez RFV, Lange N, Guy R, et al. Photodynamic therapy of skin cancer:
controlled drug delivery of 5-ALA and its esters. Adv Drug Deliv Rev 2004;56:
77e94.
2. De Rosa F, Bentley MV. Photodynamic therapy of skin cancers: sensitizers,
clinical studies and future directives. Pharm Res 2000;17:1447e55.
3. Casas A, Fukuda H, Meiss R, et al. Topical and intratumoral photodynamic
therapy with 5-aminolevulinic acid in a subcutaneous murine mammary
adenocarcinoma. Cancer Lett 1999;141:29e38.
4. Dougherty TJ, Grindey GB, Fiel R, et al. Photoradiation therapy. II. Cure of
animal tumors with hematoporphyrin and light. J Natl Cancer Inst 1975;55:
115e21.
5. Sibata CH, Colussi VC, Oleinick NL, et al. Photodynamic therapy in oncology.
Expert Opin Pharmacother 2001;2:917e27.
6. Sil S, Bose T, Roy D, et al. Protoporphyrin IX-induced structural and functional
changes in human red blood cells, haemoglobin and myoglobin. J Biosci
2004;29:281e91.
7. Fang JY, Leu YL. Prodrug strategy for enhancing drug delivery via skin. Curr
Drug Discov Technol 2006;3:211e24.
8. Benson HA. Transdermal drug delivery: penetration enhancement techniques.
Curr Drug Deliv 2005;2:23e33.
9. Pathan IB, Setty CM. Chemical penetration enhancers for transdermal drug
delivery systems. Trop J Pharm Res 2009;8:173e9.
10. He N, Warner KS, Chantasart D, et al. Mechanistic study of chemical skin
permeation enhancers with different polar and lipophilic functional groups.
J Pharm Sci 2004;93:1415e30.
11. Kamal MA, Nabekura T, Kitagawa S. Permeability of ionized salicylate deriva-
tives through guinea pig dorsal skin. Chem Pharm Bull (Tokyo) 2005;53:441e3.
12. Simonetti LD, Gelfuso GM, Barbosa JC, et al. Assessment of the percutaneous
penetration of cisplatin: the effect of monoolein and the drug skin penetration
pathway. Eur J Pharm Biopharm 2009;73:90e4.
13. Davidson A, Al-Qallaf B, Das DB. Transdermal drug delivery by coated micro-
needles: geometry effects on effective skin thickness and drug permeability.
AIChE J 2008;86:1196e206.14. Scheindlin S. Transdermal drug delivery: past, present, future. Mol Interv
2004;4:308e12.
15. Tanner T, Marks R. Delivering drugs by the transdermal route: review and
comment. Skin Res Technol 2008;14:249e60.
16. Finnin BC, Morgan TM. Transdermal penetration enhancers: applications,
limitations, and potential. J Pharm Sci 1999;88:955e8.
17. Godin B, Touitou E. Transdermal skin delivery: predictions for humans from in
vivo, ex vivo and animal models. Adv Drug Deliv Rev 2007;59:1152e61.
18. Lanke SS, Kolli CS, Strom JG, et al. Enhanced transdermal delivery of low
molecular weight heparin by barrier perturbation. Int J Pharm 2009;365:26e33.
19. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous
protoporphyrin IX: basic principles and present clinical experience.
J Photochem Photobiol B 1990;6:143e8.
20. Dijkstra AT, Majoie IM, van Dongen JW, et al. Photodynamic therapy with violet
light and topical 6-aminolaevulinic acid in the treatment of actinic keratosis,
Bowen’s disease and basal cell carcinoma. J Eur Acad Dermatol Venereol
2001;15:550e4.
21. Zeitouni NC, Oseroff AR, Shieh S. Photodynamic therapy for nonmelanoma skin
cancers. Current review and update. Mol Immunol 2003;39:1133e6.
22. Leman JA, Dick DC, Morton CA. Topical 5-ALA photodynamic therapy for the
treatment of cutaneous T-cell lymphoma. Clin Exp Dermatol 2002;27:516e8.
23. De Rosa FS, Marchetti JM, Thomazini JA, et al. A vehicle for photodynamic
therapy of skin cancer: inﬂuence of dimethylsulphoxide on 5-aminolevulinic
acid in vitro cutaneous permeation and in vivo protoporphyrin IX accumula-
tion determined by confocal microscopy. J Control Release 2000;65:359e66.
24. Lee WR, Shen SC, Pai MH, et al. Fractional laser as a tool to enhance the skin
permeation of 5-aminolevulinic acid with minimal skin disruption: a compar-
ison with conventional erbium:YAG laser. J Control Release 2010;145:124e33.
25. Donnelly RF, McCarron PA, Woolfson AD. Drug delivery of aminolevulinic acid
from topical formulations intended for photodynamic therapy. Photochem
Photobiol 2005;81:750e67.
26. Wiegell SR, Stender IM, Na R, et al. Pain associated with photodynamic therapy
using 5-aminolevulinic acid or 5-aminolevulinic acid methylester on tape-
stripped normal skin. Arch Dermatol 2003;139:1173e7.
27. Di Venosa G, Hermida L, Fukuda H, et al. Comparation of liposomal formula-
tions of ALA undecanoyl ester for its use in photodynamic therapy. J Photochem
Photobiol B 2009;96:152e8.
28. Morrow DI, McCarron PA, Woolfson AD, et al. Hexyl aminolaevulinate is a more
effective topical photosensitiser precursor than methyl aminolaevulinate and
5-aminolaevulinic acids when applied in equimolar doses. J Pharm Sci
2010;99:3486e98.
29. van den Akker JT, Iani V, Star WM, et al. Topical application of 5-aminolevulinic
acid hexyl ester and 5-aminolevulinic acid to normal nude mouse skin:
differences in protoporphyrin IX ﬂuorescence kinetics and the role of the
stratum corneum. Photochem Photobiol 2000;72:681e9.
30. Gaullier JM, Berg K, Peng Q, et al. Use of 5-aminolevulinic acid esters to improve
photodynamic therapy on cells in culture. Cancer Res 1997;57:1481e6.
31. De Rosa FS, Tedesco AC, Lopez RF, et al. In vitro skin permeation and retention
of 5-aminolevulinic acid ester derivatives for photodynamic therapy. J Control
Release 2003;89:261e9.
32. Juzeniene A, Juzenas P, Ma LW, et al. Topical application of 5-aminolaevulinic
acid, methyl 5-aminolaevulinate and hexyl 5-aminolaevulinate on normal
human skin. Br J Dermatol 2006;155:791e9.
33. Lopez RF, Bentley MV, Begona Delgado-Charro M, et al. Optimization of ami-
nolevulinic acid delivery by iontophoresis. J Control Release 2003;88:65e70.
34. Lopez RF, Bentley MV, Delgado-Charro MB, et al. Enhanced delivery of 5-
aminolevulinic acid esters by iontophoresis in vitro. Photochem Photobiol
2003;77:304e8.
35. Shen SC, Lee WR, Fang YP, et al. In vitro percutaneous absorption and in vivo
protoporphyrin IX accumulation in skin and tumors after topical 5-amino-
levulinic acid application with enhancement using an erbium:YAG laser.
J Pharm Sci 2006;95:929e38.
36. Donnelly RF, Morrow DI, McCarron PA, et al. Microneedle-mediated intra-
dermal delivery of 5-aminolevulinic acid: potential for enhanced topical
photodynamic therapy. J Control Release 2008;129:154e62.
37. Mikolajewska P, Donnelly RF, Garland MJ, et al. Microneedle pre-treatment of
human skin improves 5-aminolevulininc acid (ALA)- and 5-aminolevulinic acid
methyl ester (MAL)-induced PpIX production for topical photodynamic
therapy without increase in pain or erythema. Pharm Res 2010;27:2213e20.
38. Ma L, Moan J, Peng Q, et al. Production of protoporphyrin IX induced by 5-
aminolevulinic acid in transplanted human colon adenocarcinoma of nude
mice can be increased by ultrasound. Int J Cancer 1998;78:464e9.
39. Guy RH. Transdermal drug delivery. Handb Exp Pharmacol 2010;197:399e410.
40. Lopez RF, Bentley MV, Delgado-Charro MB, et al. Iontophoretic delivery of 5-
aminolevulinic acid (ALA): effect of pH. Pharm Res 2001;18:311e5.
41. Cleary GW. Microneedles for drug delivery. Pharm Res 2010;28:1e6.
42. Donnelly RF, Singh TRR, Woolfson AD. Microneedle-based drug delivery
systems: microfabrication, drug delivery, and safety. Drug Deliv 2010;17:
187e207.
43. Park JH, Choi SO, Seo S, et al. A microneedle roller for transdermal drug
delivery. Eur J Pharm Biopharm 2010;76:282e9.
44. Nyborg WL. Ultrasonic microstreaming and related phenomena. Br J Cancer
Suppl 1982;5:156e60.
45. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev 2004;56:
603e18.
L.-W. Zhang et al. / Dermatologica Sinica 29 (2011) 1e7 746. Malik Z, Kostenich G, Roitman L, et al. Topical application of 5-aminolevulinic
acid, DMSO and EDTA: protoporphyrin IX accumulation in skin and tumours of
mice. J Photochem Photobiol B 1995;28:213e8.
47. Pierre MB, Ricci Jr E, Tedesco AC, et al. Oleic acid as optimizer of the skin
delivery of 5-aminolevulinic acid in photodynamic therapy. Pharm Res
2006;23:360e6.
48. Bunke A, Zerbe O, Schmid H, et al. Degradation mechanism and stability of 5-
aminolevulinic acid. J Pharm Sci 2000;89:1335e41.
49. Fang JY, Wu PC, Fang CL, et al. Intravesical delivery of 5-aminolevulinic acid
from water-in-oil nano/submicron-emulsion systems. J Pharm Sci 2010;99:
2375e85.
50. Fang JY, Hong CT, Chiu WT, et al. Effect of liposomes and niosomes on skin
permeation of enoxacin. Int J Pharm 2001;219:61e72.
51. Casas A, Fukuda H, Batlle AM. Tissue distribution and kinetics of endogenous
porphyrins synthesized after topical application of ALA in different vehicles. Br
J Cancer 1999;81:13e8.
52. Casas A, Fukuda H, Di Venosa G, et al. The inﬂuence of the vehicle on the
synthesis of porphyrins after topical application of 5-aminolaevulinic acid.
Implications in cutaneous photodynamic sensitization. Br J Dermatol 2000;143:
564e72.53. Valenta C, Auner BG, Loibl I. Skin permeation and stability studies of 5-ami-
nolevulinic acid in a new gel and patch preparation. J Control Release 2005;107:
495e501.
54. Zucker D, Marcus D, Barenholz Y, et al. Liposome drugs’ loading efﬁciency:
a working model based on loading conditions and drug’s physicochemical
properties. J Control Release 2009;139:73e80.
55. Fang JY. Nano- or submicron-sized liposomes as carriers for drug delivery.
Chang Gung Med J 2006;29:358e62.
56. Korting HC, Schafer-Korting M. Carriers in the topical treatment of skin disease.
Handb Exp Pharmacol 2010;197:435e68.
57. Pierre MB, Tedesco AC, Marchetti JM, et al. Stratum corneum lipids liposomes
for the topical delivery of 5-aminolevulinic acid in photodynamic therapy of
skin cancer: preparation and in vitro permeation study. BMC Dermatol
2001;1:5.
58. Auner BG, Valenta C, Hadgraft J. Inﬂuence of lipophilic counter-ions in
combination with phloretin and 6-ketocholestanol on the skin permeation of
5-aminolevulinic acid. Int J Pharm 2003;255:109e16.
59. Araujo LM, Thomazine JA, Lopez RF. Development of microemulsions to topi-
cally deliver 5-aminolevulinic acid in photodynamic therapy. Eur J Pharm
Biopharm 2010;75:48e55.
